IL-1RAcP/IL-1R3 His Tag Protein, Mouse
IL-1RAcP/IL-1R3 His Tag Protein, Mouse
Price:
Regular price
$376.00 USD
Regular price
Sale price
$376.00 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Mouse |
| Synonyms | IL-1RAcP, IL-1R3, C3orf13, IL1RAP |
| Accession | Q61730 |
| Amino Acid Sequence | Ser21-Thr367, with C-terminal 10*His SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKYNYSTAHSSGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSAMRFPVHKMYIEHGIHKITCPNVDGYFPSSVKPSVTWYKGCTEIVDFHNVLPEGMNLSFFIPLVSNNGNYTCVVTYPENGRLFHLTRTVTVKVVGSPKDALPPQIYSPNDRVVYEKEPGEELVIPCKVYFSFIMDSHNEVWWTIDGKKPDDVTVDITINESVSYSSTEDETRTQILSIKKVTPEDLRRNYVCHARNTKGEAEQAAKVKQKVIPPRYTVELACGFGATGGGSGGGSHHHHHHHHHH |
| Expression System | HEK293 |
| Molecular Weight | 48-68kDa |
| Purity | >95% by SDS-PAGE |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1、Boraschi D. et al. (2013) The interleukin-1 receptor family. Semin Immunol. 25(6): 394-407. |
Background
IL-1 Receptor Accessory Protein (IL-1 RAcP), also known as IL-1 R3, is a ubiquitously expressed 70-90 kDa member of the Interleukin-1 receptor family of proteins. It serves as a non-ligand-binding component of the receptors for IL-1 alpha, IL-1 beta, IL-33, and IL-36. Interleukin-1 receptor accessory protein (IL1RAP) is consistently overexpressed across multiple genetic subtypes of acute myeloid leukemia (AML) and other myeloid malignancies, including at the stem cell level, and is emerging as a novel therapeutic target.
Picture
Picture
SDS-PAGE
1μg (R: reducing conditions, N: non-reducing conditions).
